Page content

Our ecosystem

NeuroXTek is built as a national-to-global ecosystem for responsible breakthrough neurotechnology. The proposal brings together Sweden’s leading neurotechnology-relevant research environments, signed intents-to-collaborate, and a broad Swedish innovation ecosystem capable of moving breakthrough neurotechnology from mission-driven research to validated use.

This page gives an overview of the players represented in the submitted NeuroXTek Excellence Cluster plan and the ecosystem capacity already mobilized around Sweden’s ambition to become a global leadership environment for responsible neurotechnology by 2036. See The NeuroXTek Alliance page for more information on the current members of our Alliance that support NeuroXTek.

Participating resarchers’ organizations

Our 15 participating researchers (formal co-applicants/co-PIs) represent the following universities and research institutes from throughout Sweden:

University of Gothenburg
Karolinska Institutet
Chalmers University of technology
KTH Royal Institute of Technology
Linköping University
Stockholm University
Institute for Future Studies

Swedish and global intent to collaborate

Our innovation plan formally includes letters of intent from 15 organizations, but many more have already expressed their intent to collaborate with signed LOIs:

List of organizations

Sahlgrenska University Hospital provides NeuroXTek with a core clinical anchor, connecting breakthrough neurotechnology to patient needs, clinical workflows, validation environments, and implementation pathways.
Medtronic strengthens NeuroXTek’s global neurotechnology and neuromodulation relevance, bringing insight into clinical translation, regulatory pathways, device development, and international scale-up.
Roche adds major pharma and diagnostics expertise, strengthening NeuroXTek’s capacity in biomarkers, neurodegeneration, clinical validation, and international translational credibility.
Elekta connects NeuroXTek to a Swedish global medtech leader, reinforcing the cluster’s position in advanced clinical technologies, precision healthcare, and nationally anchored industrial competitiveness.
Blackrock Neurotech strengthens NeuroXTek’s direct link to invasive brain-computer interfaces, bidirectional cortical neuroprostheses, first-in-human translation, and next-generation neural-interface development.
AI Sweden provides a critical national AI ecosystem anchor, supporting NeuroXTek’s ambitions in multimodal neurodata, benchmarking, responsible AI, predictive modelling, and scalable AI-enabled neurotechnology.
SIISH 2.0 strengthens NeuroXTek’s healthcare implementation pathway by linking neurotechnology innovation to existing structures for clinical adoption, scale-up, and system-level transformation.
Industrifonden adds a high-value national capital perspective, strengthening NeuroXTek’s capacity to support venture readiness, follow-on financing, and the scale-up of neurotechnology opportunities.
Almi Invest complements NeuroXTek’s capital pathway by supporting early-stage financing perspectives for emerging opportunities, start-ups, and lower-maturity innovation trajectories.
IMEC brings international deep-tech excellence in semiconductor-enabled innovation, strengthening NeuroXTek’s routes toward advanced sensors, implantable systems, neurotechnology hardware, and scalable platform technologies.
European Brain Council
The European Brain Council strengthens NeuroXTek’s European positioning in brain health, policy engagement, responsible neurotechnology, international legitimacy, and emerging standards.
BioArctic adds strong Swedish neurodegeneration and disease-biology expertise, reinforcing NeuroXTek’s work on amyloid biology, biomarkers, mechanistic stratification, and pharma-facing translation.
IRLAB strengthens NeuroXTek’s Parkinson’s disease and neuropharmacology relevance, supporting translational routes that connect mechanistic modelling, treatment development, and brain-health innovation.
AbbVie adds global pharma perspective and strengthens NeuroXTek’s strategic relevance in brain health, clinical translation, treatment development, and international market-facing innovation.
Flow Neuroscience strengthens NeuroXTek’s link to home-based and consumer-facing neurotechnology, supporting responsible validation, prevention-oriented models, and scalable brain-health interventions.
Amyloidia adds focused relevance in amyloid diagnostics and blood-based biomarker development, strengthening NeuroXTek’s capacity for early detection, stratification, and neurodegeneration-related translation.
Graphensic contributes deep-tech materials expertise relevant to advanced sensors, silicon carbide and graphene-based technologies, and future hardware routes for neurotechnology platforms.
2D-Tech adds expertise in two-dimensional materials and device development, supporting NeuroXTek’s long-term hardware routes for advanced sensing, fabrication, and platform technologies.
DeepLightVision strengthens NeuroXTek’s potential in optics, imaging, and light-based neurotechnology interfaces, contributing to advanced measurement and visualization routes across the cluster.
Eclipse Optics adds optical and imaging-hardware relevance, supporting NeuroXTek’s capacity to connect advanced instrumentation with research, validation, and future neurotechnology applications.
BrainZell contributes cellular and model-system relevance, supporting NeuroXTek’s MAPS mission through experimental platforms for mechanistic understanding, neurodevelopmental research, and translational model development.
Oscillution adds neurotechnology SME perspective, strengthening NeuroXTek’s connection to emerging companies and market-facing innovation routes within the Swedish neurotechnology ecosystem.
Aphygo contributes to NeuroXTek’s broader innovation ecosystem by adding entrepreneurial and translational perspective as the Alliance builds pathways from research opportunities to practical use.
NeuroOne strengthens NeuroXTek’s neural-interface and clinical-device relevance, supporting translation of advanced sensing, recording, and stimulation technologies toward validated neurotechnology applications.

Our Swedish innovation ecosystem

Our innovation plan formally includes CVs from 15 innovation leaders from many strong innovation offices and organizations throughout Sweden. Here, we list those beyond the research and innovation offices at our participating researchers’ universities and research institutes and those that contributed with LOIs: